GU Cancers 2019 | Sacituzumab govitecan in the treatment of metastatic urothelial carcinoma

Jeanny Aragon-Ching

Jeanny Aragon-Ching, MD, FACP, of the Inova Schar Cancer Institute, Fairfax, Canada, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, where she discusses the promising response rates in the use of the antibody-drug conjugate sacituzumab govitecan in the treatment of metastatic urothelial carcinoma from the TROPHY U-01 study (NCT03547973).

Share this video